Article
Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Oct 2013
Chengwei Xu, Xiaoli Ma, Yuan Zhang, Li Pang, Shengjiang Wang, Chao Yu, Yunshan Wang
Abstract excerpt
Impairment of fibrinolytic function plays an important role in the mechanism of thrombotic disorders in cancer patients. Thrombin-activatable fibrinolysis inhibitor (TAFI) has an antifibrinolytic effect as it can remove partially degraded fibrin C-terminal lysine residues and reduce plasmin formation. The purpose of this study was to investigate whether blood TAFI levels and TAFI Thr325Ile polymorphism could be a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
